The stock price of Celldex Therapeutics Inc (NASDAQ: CLDX) has dropped by -1.65 compared to previous close of 21.17. Despite this, the company has seen a gain of 1.56% in its stock price over the last five trading days. globenewswire.com reported 2025-06-14 that HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1.
Is It Worth Investing in Celldex Therapeutics Inc (NASDAQ: CLDX) Right Now?
Moreover, the 36-month beta value for CLDX is 1.14. Analysts have varying opinions on the stock, with 11 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for CLDX is 64.51M and currently, short sellers hold a 12.14% of that float. On June 27, 2025, CLDX’s average trading volume was 946.96K shares.
CLDX’s Market Performance
The stock of Celldex Therapeutics Inc (CLDX) has seen a 1.56% increase in the past week, with a 11.58% rise in the past month, and a 4.20% gain in the past quarter. The volatility ratio for the week is 5.85%, and the volatility levels for the past 30 days are at 6.61% for CLDX. The simple moving average for the past 20 days is 1.30% for CLDX’s stock, with a -14.35% simple moving average for the past 200 days.
Analysts’ Opinion of CLDX
Many brokerage firms have already submitted their reports for CLDX stocks, with Canaccord Genuity repeating the rating for CLDX by listing it as a “Buy.” The predicted price for CLDX in the upcoming period, according to Canaccord Genuity is $64 based on the research report published on April 28, 2025 of the current year 2025.
Morgan Stanley, on the other hand, stated in their research note that they expect to see CLDX reach a price target of $46. The rating they have provided for CLDX stocks is “Overweight” according to the report published on March 20th, 2025.
UBS gave a rating of “Buy” to CLDX, setting the target price at $44 in the report published on February 13th of the current year.
CLDX Trading at 3.72% from the 50-Day Moving Average
After a stumble in the market that brought CLDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.70% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLDX starting from Marucci Anthony S, who purchase 11,500 shares at the price of $26.82 back on Nov 11 ’24. After this action, Marucci Anthony S now owns 40,284 shares of Celldex Therapeutics Inc, valued at $308,430 using the latest closing price.
Stock Fundamentals for CLDX
Current profitability levels for the company are sitting at:
- -28.74 for the present operating margin
- 0.79 for the gross margin
The net margin for Celldex Therapeutics Inc stands at -23.66. The total capital return value is set at -0.31. Equity return is now at value -23.20, with -22.24 for asset returns.
Based on Celldex Therapeutics Inc (CLDX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -50.03.
Currently, EBITDA for the company is -191.9 million with net debt to EBITDA at 0.06. When we switch over and look at the enterprise to sales, we see a ratio of 181.5. The receivables turnover for the company is 7.1for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 21.67.
Conclusion
To wrap up, the performance of Celldex Therapeutics Inc (CLDX) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
